drugset / Trial / NCT07600723

A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)

NCT07600723

Phase 4 Not yet recruiting 30 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelTreatment

Summary

Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH). In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. This causes high blood pressure in the lungs and can overwork the heart. PAH can make it hard to breathe and be active. Researchers want to learn if sotatercept, the study medicine, can be given with standard treatment to help treat PAH. The standard treatment (the usual treatment) for PAH includes one or multiple medicines. However, these may not fully work or treat the symptoms of PAH in some people. The goal of this study is to learn about the safety and tolerability of sotatercept when it is given with standard treatment to people in India.

Timeline

Start
2026-07-15
Primary completion
2028-04-03
Completion
2028-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotatercept Protein / enzyme biologic 0.7 mg/kg Subcutaneous